Skip to main content

Advertisement

SpringerLink
Log in

Tumor location and patient age predict biological signatures of high-grade gliomas

  • Original Article
  • Published:
Neurosurgical Review Aims and scope Submit manuscript

Abstract

Prognostic factors for high-grade gliomas include patient age, IDH1 mutation, MGMT methylation, and Ki67 value. We assessed the predictive role of topographic location of gliomas for their biological signatures. Collecting all neuroradiological and histological data of patients with histologically proven HGG, we performed a retrospective monocentric study. A predictive value of frontal location for a lower Ki67 value (especially in the left hemisphere) and mutation of IDH1 (especially in the right hemisphere) was found. Temporal location was predictive for IDH1 wild-type. Involvement of the parietal lobe was found to be predictive of methylated MGMT, while insular lobe involvement predicted an unmethylated MGMT. There was no statistically significant difference of IDH1 mutation and MGMT methylation between left and right sides.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Altieri R, Agnoletti A, Quattrucci F et al (2014) Molecular biology of gliomas: present and future challenges. Transl Med @ UniSa 10(7):29–37

    CAS  Google Scholar 

  2. Altieri R, Zenga F, Fontanella MM, Cofano F, Agnoletti A, Spena G, Crobeddu E, Fornaro R, Ducati A, Garbossa D (2015) Glioma surgery: technological advances to achieve a maximal safe resection. Surg Technol Int 27:297–302

    PubMed  Google Scholar 

  3. Brigliadori G, Foca F, Dall M, Claudia A, Melegari E, Cerasoli S, Amadori D, Calistri D (2016) Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. J Neuro-Oncol 128(2):333–339

    Article  CAS  Google Scholar 

  4. Darlix A, Deverdun J, Menjot de Champfleur N, et al (2017) IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. J Neuro-Oncol 133(1):37–45. https://doi.org/10.1007/s11060-017-2421-0

  5. Ellingson BM, Cloughesy TF, Pope WB et al (2012) Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. NeuroImage 59(2):908–916

    Article  CAS  PubMed  Google Scholar 

  6. Ellingson BM, Lai A, Harris RJ et al (2013) Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 34(3):533–540

    Article  CAS  PubMed  Google Scholar 

  7. Fiano V, Trevisan M, Trevisan E et al (2014) MGMT promoter methylation in plasma of glioma patients receiving temozolomide. J Neuro-Oncol 117(2):347–357

    Article  CAS  Google Scholar 

  8. Hamou M, Tribolet N de Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Stupp R (2005) Gene Silencing and Benefit from Temozolomide in Glioblastoma. 997–1003

  9. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S (2013) Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro-Oncology 15(1):91–96

    Article  CAS  PubMed  Google Scholar 

  10. Johannessen AL, Torp SH (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12(3):143–147

    Article  PubMed  Google Scholar 

  11. Jungk C, Mock A, Exner J et al (2016) Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC Med 14(1):170

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kanas VG, Zacharaki EI, Thomas GA, Zinn PO, Megalooikonomou V, Colen RR (2017) Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma. Comput Methods Prog Biomed 140:249–257

    Article  Google Scholar 

  13. Kickingereder P, Bonekamp D, Nowosielski M et al (2016) Radiogenomics of glioblastoma: machine learning–based classification of molecular characteristics by using multiparametric and mutiregional MR imaging features. Radiology 281(3):907–918

    Article  PubMed  Google Scholar 

  14. Kreth S, Belka C, Niyazi M, Wilhelm F (2017) Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. J Neurol 264(2):350–358. https://doi.org/10.1007/s00415-016-8355-1

  15. Lai A, Kharbanda S, Pope WB et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29(34):4482–4490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lasocki A, Tsui A, Gaillard F, Tacey M, Drummond K, Stuckey S (2017) Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci 39:170–175

    Article  CAS  PubMed  Google Scholar 

  17. Lombardi G, Pace A, Pasqualetti F et al (2015) Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). J Neuro-Oncol 125(2):359–367

    Article  CAS  Google Scholar 

  18. Lopci E, Riva M, Olivari L et al (2017) Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging 44(7):1155–1164

    Article  CAS  PubMed  Google Scholar 

  19. Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, Husband D, Shenoy A, Wong H, Jenkinson MD (2016) The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir 158(10):1943–1953

    Article  PubMed  Google Scholar 

  20. Nghiemphu PL, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM (2012) Edema, IDH1 mutational status, MGMT promoter. (August):1349–1355

  21. Paldor I, Pearce FC, Drummond KJ, Kaye AH (2016) Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors. J Clin Neurosci Off J Neurosurg Soc Australas 34:128–132

    CAS  Google Scholar 

  22. Preusser M, Hoeftberger R, Woehrer A, et al (2012) Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group 885–894

  23. Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353(8):811–822

    Article  CAS  PubMed  Google Scholar 

  24. Sanai N, Berger MS (2011) Extent of resection influences outcomes for patients with gliomas. Rev Neurol (Paris) 167(10):648–654

    Article  CAS  Google Scholar 

  25. Sanai N, Nguyen T, Ihrie RA et al (2011) Corridors of migrating neurons in the human brain and their decline during infancy. Nature 478(7369):382–386

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  CAS  PubMed  Google Scholar 

  27. Szopa W, Burley TA, Kramer-marek G, Kaspera W (2017) Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives. https://doi.org/10.1155/2017/8013575

  28. Wasserman JK, Nicholas G, Yaworski R (2015) Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. PLoS One 7:10(4):e0123890. https://doi.org/10.1371/journal.pone.0123890

  29. Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, Kang C, You Y, Wang L, Jiang T (2012) Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One 7(1):e30339. https://doi.org/10.1371/journal.pone.0030339

  30. Zlatescu MC, TehraniYazdi AR, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61(18):6713–6715

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurosurgical Unit, Department of Neuroscience, University of Turin, Turin, Italy

    Roberto Altieri, Francesco Zenga, Alessandro Ducati, Antonio Melcarne, Fabio Cofano, Marco Mammi, Giuseppe Di Perna & Diego Garbossa

  2. AOU San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy

    Riccardo Savastano

Authors
  1. Roberto Altieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Zenga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Ducati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Melcarne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabio Cofano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marco Mammi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giuseppe Di Perna
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Riccardo Savastano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Diego Garbossa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Altieri.

Ethics declarations

All procedures performed in studies involving human participants were in accordance with the ethical standards of “Azienda Ospedaliera Universitaria Città della Salute e della Scienza of Turin” and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

For this type of study formal consent is not required.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Altieri, R., Zenga, F., Ducati, A. et al. Tumor location and patient age predict biological signatures of high-grade gliomas. Neurosurg Rev 41, 599–604 (2018). https://doi.org/10.1007/s10143-017-0899-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10143-017-0899-8

Keywords

Search

Navigation